Home > Insider Trading > Filing (0001104659-21-020672)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
886163	Ligand Pharmaceuticals Inc	LGND	Pharmaceutical Preparations (2834)	770160744

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1442372	L Stephen Sabba	Dorset Management Corp 485 Underhill Blvd Suite 205 Syosset NY 11791		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-02-09	7,335	$10.12	31,766	No	4	M	Direct
Common Stock	Acquisiton	2021-02-09	7,335	$12.53	39,101	No	4	M	Direct
Common Stock	Disposition	2021-02-09	556	$208.00	38,545	No	4	S	Direct
Common Stock	Disposition	2021-02-09	14,114	$208.55	24,431	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2021-02-09	7,335	$0.00	7,335	$10.12
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2021-02-09	7,335	$0.00	7,335	$12.53

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2021-06-01	No	4	M	Direct
0		2022-05-31	No	4	M	Direct

Footnotes

These securities, as represented in Column 5, include a grant of 831 restricted shares approved by the Board of Directors of the Company at the 2020 Meeting, which shares were previously reported on a Form 4 for this Reporting Person filed on June 12, 2020, and are included on this Form 4 only to report that they will vest in full within six (6) months from the date hereof.
These securities, as represented in Column 5, were acquired by a grant of 7,335 shares approved by the Board of Directors of the Company at the 2011 Meeting and are fully vested and exerciseable as more fully described on a Form 4 for this Reporting Person filed on June 6, 2011.
These securities, as represented in Column 5, were acquired by a grant of 7,335 shares approved by the Board of Directors of the Company at the 2012 Meeting and are fully vested and exerciseable as more fully described on a Form 4 for this Reporting Person filed on June 4, 2012.